Table 1 Correlation between clinical features and pathological parameters of HER2 positive invasive breast cancer patients and pathological objective links of neoadjuvant therapy

Age ((\(\overline{x}\) ± s), year)

46.28 ± 9.37

49.32 ± 11.73

1.644^a

0.138

Clinical staging before treatment

3.008

0.222

 cT₁

21

10

67.74

 cT₂

87

69

55.77

 cT₃

30

14

68.18

Lymph node status before treatment

0.188

0.664

 positive

70

50

58.33

 negative

68

43

61.26

Chemotherapy

0.541

0.763

 AC✖4-T✖4/T✖4-AC✖4

97

68

58.79

 TCb✖6

20

11

64.52

 T✖6

21

14

60.00

TNM classification

26.913

 < 0.001

 II

115

48

70.55

 III

23

45

33.82

Pathological grading of puncture before treatment

6.307^b

0.043

 I

19

4

82.61

 II

101

69

59.41

 III

18

20

47.37

ER

15.371

 < 0.001

 positive

82

29

73.87

 negative

56

64

46.67

PR

8.859

0.003

 positive

97

46

67.83

 negative

41

47

46.59

HER2

4.748

0.029

 positive

69

33

67.65

 negative

69

60

53.49

EGFR

5.131

0.024

 positively

62

28

68.89

 negative

76

65

53.90

Ki-67

11.519

0.001

 high expression

28

38

42.42

 low expression

110

55

66.67

CDK4

36.987

 < 0.001

 positively

39

64

37.86

 negative

99

29

77.34

Breast cancer subtype

8.696

0.013

 triple-negative breast cancer

25

20

55.56

 triple-positive breast cancer

23

4

85.19

 other types

90

69

56.60

NACT

27.171

 < 0.001

 effective (CR + PR)

123

57

68.33

 ineffective (SD + PD)

15

36

29.41

Family history of cancer

0.235

0.628

 Yes

31

21

59.62

 No

107

72

59.78